Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is facing some near-term headwinds due to longer sales cycles and lower expansion from Inseyets conversions, resulting in a slower projected growth rate for CY27. However, they have taken appropriate steps to address these challenges and are expected to see continued growth in CY27, with a projected increase in EBITDA. Additionally, their solutions may face perceived privacy and human rights concerns, but they have established a strong customer base and plan to continue introducing new solutions to cross-sell and upsell existing customers. Overall, the company appears undervalued compared to its peers and continues to see growth with new product offerings.

Bears say

Cellebrite DI is facing near-term headwinds due to push-outs on a handful of large deals and lower than expected contribution from product upgrades. However, with a new CEO in place, new product launches and a strong customer base, the company is poised to accelerate growth in the future. Its dependence on government and law enforcement agencies for revenue, competition in the market, and currency fluctuations are potential risks but the company's purpose-built DI platform and strong customer relationships help reduce these risks. Despite recent setbacks, the company has strong fundamentals with 30%+ Free Cash Flow Margins and an attractive valuation compared to its peers, leading to a long-term buy recommendation.

CLBT has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 5 analysts, CLBT has a Strong Buy consensus rating as of Sep 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.